Open Access

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Event: ESC Congress 2018
Topic: Acute Coronary Syndromes
Session type: Satellite Symposium
Sponsored by Sanofi US and Regeneron Pharmaceuticals
Date: 27 August 2018
Time: 13:00 - 14:00

Session

5 presentations in this session

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Speaker: Professor D. Bhatt (Boston, US)
Thumbnail

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Speaker: Professor P. Steg (Paris, FR)
Thumbnail

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Speaker: Professor J. Jukema (Leiden, NL)
Thumbnail

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Speaker: Professor D. Bhatt (Boston, US)
Thumbnail

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Speaker: Professor D. Bhatt (Boston, US)
Thumbnail

5 speakers from this session

Professor Deepak Bhatt

Harvard Medical School, Boston (United States of America)
30 presentations
1 follower

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)
44 presentations
2 followers

Professor J Wouter Jukema

Leiden University Medical Centre, Leiden (Netherlands (The))
14 presentations
0 follower

Professor Deepak Bhatt

Harvard Medical School, Boston (United States of America)
30 presentations
1 follower

Professor Deepak Bhatt

Harvard Medical School, Boston (United States of America)
30 presentations
1 follower

This platform is supported by

logo Novo Nordisk